Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649 Meeting Abstract
| Authors: | Moehler, M.; Janjigian, Y. Y.; Shitara, K.; Garrido, M.; Gallardo, C.; Shen, L.; Yamaguchi, K.; Wyrwicz, L.; Skoczylas, T.; Bragagnoli, A.; Liu, T.; Tehfe, M.; Elimova, E.; Bruges, R.; Cleary, J. M.; Karamouzis, M.; Soleymani, S.; Lei, M.; Amaya, C. C.; Ajani, J. A. |
| Abstract Title: | Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649 |
| Meeting Title: | Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie (2023) |
| Journal Title: | Oncology Research and Treatment |
| Volume: | 46 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2023 Oct 13-16 |
| Meeting Location: | Hamburg, Germany |
| ISSN: | 2296-5270 |
| Publisher: | S. Karger AG |
| Date Published: | 2023-10-01 |
| Start Page: | 114 |
| End Page: | 115 |
| Language: | English |
| ACCESSION: | WOS:001091456900243 |
| PROVIDER: | wos |
| PUBMED: | 37788643 |
| DOI: | 10.1159/000533576 |
| Notes: | Meeting Abstract: V840 -- Source: Wos |
